CXADR

CXADR

CXADR Overview

Molecule Name
Calcium sensing receptor
Synonyms
CXADR,CAR,CAR4,6,HCAR
Drug Development Progress
Drugs in Clinical Trials5
Approved Drugs6
Highest Development StageApproved
Target Synonym
Parathyroid cell calcium-sensing receptor 1,FHH,FIH,HHC,Receptors, Calcium-Sensing,Extracellular calcium-sensing receptor,hCasR,GPRC2A,Calcium Sensing Receptor,Parathyroid Ca(2+)-Sensing Receptor 1,Severe Neonatal Hyperparathyroidism,Calcium-Sensing Receptor,HYPOC1,NSHPT,PCaR1,EIG8,HHC1,CaSR,CAR,Hypocalciuric Hypercalcemia 1
Background
Coxsackie virus and adenovirus receptor (CXADR) is also known as CAR, is a type I transmembrane glycoprotein for group B coxsackie viruses and subgroup C adenoviruses, and belongs to the CTX family of the Ig superfamily. CAR is strongly expressed in the developing central nervous system. It functions as a homophilic and also as a heterophilic cell adhesion molecule through its interactions with extracellular matrix glycoproteins such as: fibronectin, agrin, laminin-1 and tenascin-R. Human CXADR protein contains a signal sequence, a extracellular domain (ECD) with a V­ type (D1) and a C2­ type (D2) Ig­like domain, a  transmembrane segment and a intracellular domain. D1 is thought to be responsible for homodimer formation in trans within tight junctions, and is necessary and sufficient for adenovirus binding. Variants of CXADR are attached to the cell membrane by a GPI- anchor.

CXADR Product List

No Data
You Have Viewed 0 Of 0 Results
  • 1

Can’t find what you need?

Submit your requirements and our technical
team will help.

Clinical Drug Information

English NameResearch CodeHighest Development StageCompanyIndicationClinical Trial
Encaleret sulfateMK-5442; JTT-305; BBP-305; CLTX-305Phase 3 ClinicalJapan Tobacco (Hong Kong) Ltd
Osteoporosis; Hypocalcemia; Osteoporosis, Postmenopausal; Hypoparathyroidism
Details
SHR-6508SHR-6508Phase 3 ClinicalShanghai Hengrui Pharmaceutical Co Ltd
Hyperparathyroidism, Secondary; Kidney Diseases; Renal Insufficiency, Chronic; Hyperparathyroidism
Details
LNP-1892LNP-1892Phase 2 ClinicalLupin Ltd
Hyperparathyroidism
Details
DS-9194bDS-9194bPhase 1 ClinicalDaiichi Sankyo Co Ltd
Osteoporosis
Details
RT-102(Rani)RT-102Phase 1 ClinicalRani Therapeutics Holdings Inc
Osteoporosis
Details

Marketed Drug Information

English NameResearch CodeHighest Development StageCompanyFirst Brand NameFirst Approved CountryFirst IndicationFirst Approved CompanyFirst Approved DateIndicationClinical Trial
UpacicalcetSK-1403; AJT-240ApprovedAjinomoto Co Incウパシタ, UpasitaJapanHyperparathyroidism, SecondarySanwa Kagaku Kenkyusho Co Ltd2021-06-23
Hyperparathyroidism, Secondary
Details
Parathyroid hormone (Shire)SHP-634; ALX-111; 423562; NPSP-795; rhPTH (1-84); SHP-635; rhPTH-1-84; PTH (1-84); SB-423562; PTH 1-84; NPSP-558ApprovedShireNatpara, Preotact, NatparUnited StatesHypoparathyroidismNps Pharmaceuticals, Inc2006-04-24
Osteoporosis; Bone Diseases, Endocrine; Osteoporosis, Postmenopausal; Hypocalcemia; Hypoparathyroidism; Hyperparathyroidism; Plaque psoriasis
Details
Cinacalcet HydrochlorideAMG-073.HCl; NPS-1493; AMG-073; KRN-1493ApprovedAmgen IncParareg, Sensipar, Mimpara, Regpara, 盖平, Sensipar/MimparaUnited StatesHypercalcemia; Hyperparathyroidism, SecondaryAmgen Inc2004-03-08
Hyperparathyroidism, Secondary; Rejection of renal transplantation; Hypophosphatemia; Edema, Cardiac; Nephrosis; Renal Insufficiency; Parathyroid Neoplasms; Hypercalcemia; Kidney Diseases; Hyperparathyroidism, Primary; Prostatic Neoplasms; Osteomalacia; Renal Insufficiency, Chronic; Kidney Failure, Chronic; Hyperparathyroidism; Chronic Kidney Disease-Mineral and Bone Disorder
Details
Etelcalcetide HydrochlorideONO-5163; KAI-4169; AMG-416; KAI-4169-HClApprovedAmgen IncParsabivEUHyperparathyroidism, SecondaryAmgen Europe Bv2016-11-11
Hyperparathyroidism, Secondary; Edema, Cardiac; Renal Insufficiency, Chronic; Kidney Failure, Chronic
Details
Strontium RanelateS-12911; S-12911-2; FK-481ApprovedLaboratoires ServierOsseor, Protos, Protelos, 欧思美Mainland ChinaOsteoporosis, PostmenopausalLes Laboratoires Servier2004-09-20
Osteoporosis, Postmenopausal
Details
EvocalcetKHK-7580; MT-4580ApprovedMitsubishi Tanabe Pharma CorpOrkediaJapanHyperparathyroidism, SecondaryKyowa Hakko Kirin Co Ltd2018-03-23
Hyperparathyroidism, Secondary; Parathyroid Neoplasms; Hyperparathyroidism, Primary; Hyperparathyroidism
Details